Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi Is Set To Soar After COVID-19 Vaccine News

Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) and Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014), in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the "Offer Document") approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the "AFM") and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ''FSMA''). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi and Kiadis satisfy competition condition related to the tender offer

AstraZeneca

Biogen

BioNTech SE

GlaxoSmithKline

Moderna

Pfizer

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

Sanofi Has A Promising Earnings Outlook

CRISPR Therapeutics

Editas Medicine

Eli Lilly

Novo Nordisk

Roche Holding AG

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

Orange

UBS Group AG

Value investors should take the time to have a look at the following securities, as their share prices are trading below the Peter Lynch earnings line, indicating possible value opportunities.

A Trio of Stocks Trading Below the Peter Lynch Earnings Line

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - October 2020

Disclosure of trading in own shares from November 23, 2020 to November 27, 2020

Sanofi: Disclosure of trading in own shares

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.

Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 7, paragraph 1 sub a of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) (the "Decree") in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the "Offer Document") approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the "AFM") and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ''FSMA''). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Update on the intended offer by Sanofi for Kiadis

Bayer AG

British American Tobacco

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Merck

Philip Morris

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The December 2020 Heat Map

The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.

Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval

Generation PMCA recently released its Q3 2020 Investor Letter. The fund is managed by co-founders Randall Abramson and Herb Abramson. The investment firm serves its clients through two distinct areas: Portfolio Management and Capital Advisory services. You should check out Generation PMCA's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Is Sanofi (SNY) a Smart Long-term Buy?

BAE Systems PLC

Diageo

L'Oreal SA

Nestle SA

Novartis

Tencent Holdings Limited

Unilever

As dividend growth investors, we know that wide moat stocks make a good starting point, but it is just one of many considerations on our hunt for high-quality dividend growth stocks. The stocks I'm covering in this article cover both developed and emerging markets.

23 International Wide Moat Dividend Growth Stocks

The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.

Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag

Johnson & Johnson

Novavax

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know

Bristol-Myers

SPDR S&P Pharmaceuticals ETF

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

French healthcare giant Sanofi has invested 50 million euros ($59 million) into Jeito Capital, an investment firm dedicated to biotech and biopharma, in a deal which Sanofi said would support French and European healthcare innovation.

Healthcare group Sanofi invests 50 million euros in Jeito Capital

France's Sanofi, one of the world's biggest pharmaceutical companies, has invested €50 million ($59 million) in venture capital firm Jeito Capital, Jeito CEO Rafaèle Tordjman said on Friday. Jeito Capital, a Paris-based venture capital firm, plans to invest in biopharma and biotech companies across all different funding stages. Sanofi is the world's fifth-largest drugmaker by prescription sales. Its better known over-the-counter brands include anti-acid products such as Rolaids and Zantac.

French drugmaker Sanofi has just invested $59 million in biotech investor Jeito Capital to fund innovation in the biopharma pipeline

Alexion Pharma

Amgen

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

Campbell Soup

Science Applications International

These companies haven't been fully recognized by the market, but are sure-fire revenue (and dividend) deliverers.

Three Top Value Stocks to Buy in November

BRIDGEWATER, N.J., Nov. 3, 2020 /PRNewswire/ -- Sanofi has won the prestigious International Society for Pharmaceutical Engineering (ISPE) Overall Facility of the Year Award for its digitally-enabled continuous biomanufacturing facility located in Framingham, Mass. This marks the second...

Sanofi's factory of the future named world's best overall facility by International Society for Pharmaceutical Engineering

The company says the deal will bolster its cancer immunotherapy efforts.

News for Sanofi Stock (SNY)